Rather, chemotherapies, causing DC activation, enhanced crosspresentation, lymphodepletion, and reduction of immunosuppressive leukocytes, act synergistically with vaccines or adoptive T cell transfer. Here, I discuss the considerations for generating promising therapeutic antitumor vaccines that use DCs. 展开...
For Provencio,21 progression-free survival was used instead of event-free survival. Chemo-IO indicates chemoimmunotherapy. aStage IIIA. bStage IIIB. Figure 3. Pooled Risk Ratios (RRs) for Pathological Outcomes Across Randomized Clinical Trials View LargeDownload Pooled RRs comparing neoadjuvant chemo...
Currently, one CTLA-4 inhibitor and five PD-1 or PD-L1 inhibitors have been approved by the FDA for the treatment of various cancers [19]. Compared to conventional chemotherapies, overall survival rates have indeed improved [99]. However, the disadvantages still exist. Firstly, serious adverse...
During a Targeted Oncology™ Case-Based Roundtable™ event, Raja Mudad, MD, discussed factors that influence the choice of immunotherapy or chemoimmunotherapy for a patient with metastatic non–small cell lung cancer. Raja Mudad, MD (Moderator) Medical Director Sy...
Immunotherapy Resources Additional resources help you learn more about immunotherapy: Immunotherapy Fact Sheet Immunotherapy: The Next Frontier American Society of Clinical Oncologists American Cancer Society National Cancer Institute Chemo Care
of recurrence and treatment resistance. The development of chemoresistant disease leads to recurrence within 16–22 months and a low 5-year survival rate of approximately 27%. More than one-third of OC patients present with malignant ascites at diagnosis, and the development of ascites is a ...
The remaining 10 studies compared DC-CIK immunotherapy plus chemotherapies with chemotherapies alone. It is interesting that one of these studies utilized bevacizumab in two arms as an additional immunotherapy. Further details, such as cell dose and treatment duration, are provided in Supplementary ...
I think that chemo/IO combinations in resectable NSCLC, it's going to be the way of the future. It's a great way to get patients the most advanced treatment we have upfront while they're still able to tolerate it, and if we're able to show that the pathologic response rates...
Recent appreciations of the immune regulatory effects of these therapeutic agents have led to the exploration of their utilization in combination with immune checkpoint inhibitors, aiming to achieve synergetic effects and to improve the response and durability of immunotherapy. Here, we will provide an...
Therapeutic HPV vaccines may potentially be combined with other therapeutic modalities such as chemotherapy, radiation therapy, or other therapeutic agents to augment the therapeutic vaccine effects.[114,183–188] Several chemotherapies and radiotherapies have been shown to enhance the potency of therapeut...